Study summary

A third-generation pill worked in people resistant to ponatinib or asciminib

Olverembatinib US study · 80 people, phase 1b · Published January 2025, JAMA Oncology

61%complete cytogenetic response (chronic phase)

What was tested

Olverembatinib, a third-generation BCR::ABL1 inhibitor approved in China, for CML or Ph-positive ALL resistant to at least two earlier pills, including some resistant to ponatinib or asciminib.

What they found

In chronic-phase CML, 61% had a complete cytogenetic response and 42% a major molecular response.
Serious treatment-related side effects occurred in 15%, none fatal.

What it means

Led to the global POLARIS-2 phase 3 trial against bosutinib.

JAMA Oncol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.